Ovarian Cancer Canada has received a request from Canada’s Drug Agency (CDA) to connect with patient advocates who have lived experience with taking the drug trametinib. The CDA’s Formulary Management Expert Committee are reviewing the drug for its effectiveness and impact on patient quality of life. We are looking for a volunteer to attend and speak to the committee during a virtual meeting in January 2025, OCC staff will also be attending. Please comment on this post or email atadman@ovariancancer.orgdirectly by Nov. 26 if you are interested in this opportunity, more information will be shared at that time. Thank you!